The company is confident that it is on to something special with its novel anti-growth differentiation factor-15 (GDF-15) ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, ...

VBI Vaccines is recalling PreHevbrio and shutting down operations amid bankruptcy. Despite FDA approval in 2021, the ...

Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.

Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano (pictured, above) as chief business ...

Australia’s CSL Behring (ASX: CSL) plans to shut down its Californian R&D facility focused on cell and gene therapies by ...

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...